Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to evaluate infusion related reactions associated with rituximab or ocrelizumab and their effect on the cytokine profiles of patients with Multiple Sclerosis

Trial Profile

Study to evaluate infusion related reactions associated with rituximab or ocrelizumab and their effect on the cytokine profiles of patients with Multiple Sclerosis

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 27 Apr 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocrelizumab (Primary) ; Rituximab
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 27 Apr 2018 Results (n=40) assessing characterize the cytokine changes associated with antiCD20 therapies, were presented at the 70th Annual Meeting of the American Academy of Neurology.
    • 20 Nov 2017 New trial record
    • 28 Oct 2017 Results presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top